Real‐world effectiveness of sodium‐glucose cotransporter‐2 inhibitors on the progression of chronic kidney disease in patients without diabetes, with and without albuminuria

Documents similaires

• Early reduction in albuminuria is associated with a steeper ‘dip’ in initial estimated glomerular filtration rate but favourable long‐term kidney outcomes in people with diabetes receiving sodium‐glucose cotransporter‐2 inhibitors
  par: Yi‐Wei Kao, et autres
  Publié: (2024)
• Uninephrectomy and sodium‐glucose cotransporter 2 inhibitor administration delay the onset of hyperglycemia
  par: Yuri Sakai Ishizaki, et autres
  Publié: (2024)
• Sodium‐glucose cotransporter 2 inhibitors reduce albuminuria in patients with Fabry disease: a real‐world case series
  par: Anthea Tsatsaronis, et autres
  Publié: (2024)
• Sodium–glucose cotransporter 2 inhibitors for hypertension in cardiovascular–kidney–metabolic syndrome
  par: Chunxiang Xu, et autres
  Publié: (2025)
• The effect of sodium‐glucose cotransporter‐2 inhibitors on inflammatory biomarkers: A meta‐analysis of randomized controlled trials
  par: Leonardo Buttice, et autres
  Publié: (2024)